title: IGF-I in the clinics: Use in retinopathy of prematurity.
abstract: Retinopathy of prematurity is a potentially blinding disease, which is associated with low neonatal IGF-I serum concentrations and poor growth. In severe cases impaired retinal vessel growth is followed by pathologic neovascularization, which may lead to retinal detachment. IGF-I may promote growth even in catabolic states. Treating preterm infants with recombinant human (rh) IGF-I to concentrations normally found during gestation has been suggested to have a preventative effect on ROP. A recent phase 2 study treating infants (gestational age between 23weeks+0days and 27weeks +6days) with rhIGF-I/IGF binding protein-3 until 30 postmenstrual weeks showed no effect on ROP but a 53% reduction in severe bronchopulmonary dysplasia and 44% reduction in severe intraventricular hemorrhage. Oxygen is a major risk factor for ROP and during the phase 2 study oxygen saturation targets were increased to 90-95%, due to national guidelines, which might have affected ROP rate and severity making increased IGF-I a weaker preventative factor for ROP.
authors.affiliation: Section for Ophthalmology, Department of Clinical Neuroscience and Rehabilitation, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden. Electronic address: ann.hellstrom@medfak.gu.se.
authors.forename: Ann
authors.initials: A
authors.lastname: Hellström
authors.affiliation: Department of Clinical Sciences, Lund, Skåne University Hospital and University of Lund, Sweden.
authors.forename: David
authors.initials: D
authors.lastname: Ley
authors.affiliation: Department of Clinical Sciences, Lund, Skåne University Hospital and University of Lund, Sweden.
authors.forename: Ingrid
authors.initials: I
authors.lastname: Hansen-Pupp
authors.affiliation: Department of Neonatology, Karolinska Institute and University Hospital, Stockholm, Sweden.
authors.forename: Boubou
authors.initials: B
authors.lastname: Hallberg
authors.affiliation: Genova Neonatal Intensive Care Unit, Instituto Pediatrico Giannina Gaslini, Genova, Italy.
authors.forename: Luca A
authors.initials: LA
authors.lastname: Ramenghi
authors.affiliation: Section for Ophthalmology, Department of Clinical Neuroscience and Rehabilitation, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden.
authors.forename: Chatarina
authors.initials: C
authors.lastname: Löfqvist
authors.affiliation: Department of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Lois E H
authors.initials: LE
authors.lastname: Smith
authors.affiliation: Section for Ophthalmology, Department of Clinical Neuroscience and Rehabilitation, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden.
authors.forename: Anna-Lena
authors.initials: AL
authors.lastname: Hård
mesh_terms: D001997:Bronchopulmonary Dysplasia / Q000517:prevention & control*; D000074042:Cerebral Intraventricular Hemorrhage / Q000517:prevention & control*; D017322:Clinical Trials, Phase II as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D062071:Infant, Extremely Premature; D007231:Infant, Newborn; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000627:therapeutic use*; D007334:Insulin-Like Growth Factor I / Q000627:therapeutic use*; D010092:Oximetry; D010102:Oxygen Inhalation Therapy; D065840:Protective Factors; D011994:Recombinant Proteins / Q000627:therapeutic use*; D015861:Retinal Neovascularization / Q000517:prevention & control; D012178:Retinopathy of Prematurity / Q000517:prevention & control*; D012307:Risk Factors; D012720:Severity of Illness Index
chemical_list: D018972:Insulin-Like Growth Factor Binding Protein 3; D011994:Recombinant Proteins; D007334:Insulin-Like Growth Factor I
keywords: Fetus; IGF-I; Metabolism; Postnatal growth; Preterm infant; Preterm morbidity